Ge Long Hui·2026-03-30 09:05Core Viewpoint - The company, Tigermed (03347.HK), reported a revenue increase of 3.5% year-on-year for the fiscal year 2025, with significant profit growth driven by the recovery of the domestic biopharmaceutical industry and increased demand for clinical research outsourcing services [1][2]. Group 1: Financial Performance - Revenue rose from RMB 6.603 billion to RMB 6.833 billion, reflecting a year-on-year growth of 3.5% [1] - Profit increased by 79.8% to RMB 0.805 billion during the reporting period [1] - Profit attributable to shareholders surged by 119.2% to RMB 0.888 billion [1] - Basic earnings per share reached RMB 1.04, with a proposed final dividend of RMB 1.26 per 10 shares [1] Group 2: Industry Trends - The domestic biopharmaceutical industry is recovering, contributing to sustained demand for clinical research outsourcing services [1] - The clinical research outsourcing industry is undergoing further consolidation, leading to improved competition [1] - The company is focusing on developing business opportunities from both domestic pharmaceutical companies and large multinational pharmaceutical firms [1] Group 3: Order Growth - New orders increased significantly, with net new orders amounting to RMB 10.2 billion, representing a year-on-year growth of 20.6% [2] - The average price of new orders has stabilized and is expected to return to a growth trend in 2026 [2] - The total amount of contracts to be executed reached RMB 18.2 billion, marking a year-on-year increase of 15.4% [2]